Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Secondary prevention measures after a stroke—should they target stroke or heart disease?

Nature Clinical Practice Neurology volume 2, pages 646–647 (2006)Cite this article

boxed-textDhamoon MS et al. (2006) Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology 66: 641–646

After a stroke or TIA, clinicians should shine the spotlight on preventing stroke without losing sight of coronary disease prevention when choosing a treatment for vascular prophylaxis

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Dahlof B et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359: 995–1003

    Article  CAS  Google Scholar 

  2. Amarenco P et al. (2006) High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355: 549–559

    Article  CAS  Google Scholar 

  3. Yusuf S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. The Clopidogrel in Unstable Angina To Prevent Recurrent Events (CURE) Trial Investigators. N Engl J Med 345: 494–502

  4. Bhatt DL et al. (2006) Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 354: 1706–1717

    Article  CAS  Google Scholar 

  5. Halkes PH et al. (2006) Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367: 1665–1673

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Martina Habeck, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Professor and Chairman of the Department of Neurological Sciences at the University of Nebraska Medical Center, Omaha, NE, USA

    Pierre Fayad

Authors
  1. Pierre Fayad
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

P Fayad received honoraria from Cordis Endovascular, a Division of Johnson & Johnson, for serving on the Executive Committee of the SAPPHIRE study. He also received honoraria from Boehringer Ingelheim Pharmaceuticals for serving as a consultant and speaker. In addition, he is a local principal investigator on a multicenter study funded by Boehringer Ingelheim Pharmaceuticals.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fayad, P. Secondary prevention measures after a stroke—should they target stroke or heart disease?. Nat Rev Neurol 2, 646–647 (2006). https://doi.org/10.1038/ncpneuro0352

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneuro0352

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing